Oxford scientists identify proteins linked to future prostate cancer risk, raising hopes of earlier detection while warning that the findings are not yet ready for routine medical testing.
Scientists have discovered biological warning signs in blood samples collected more than 15 years before men were diagnosed with prostate cancer, raising hopes that future tests could identify those at risk long before the disease is discovered.
The research, led by scientists at the University of Oxford, identified proteins associated with the later development of prostate cancer, including aggressive forms that can spread and become life-threatening.
The findings, published in the medical journal European Urology, could help researchers develop more accurate methods for identifying men who need closer monitoring.
However, the study has not produced a clinically approved blood test capable of diagnosing prostate cancer 15 years in advance. The researchers identified associations between blood proteins and future cancer risk, rather than demonstrating a screening test ready for hospitals.
The development comes amid continuing debate over prostate cancer screening in Britain, where the government has supported targeted screening for certain high-risk men rather than routine screening for the entire male population.
How scientists identified prostate cancer warning signs
Researchers examined blood samples from participants in the European Prospective Investigation into Cancer and Nutrition, a long-running international study.
The analysis included 982 men who subsequently developed prostate cancer and 1,573 other men selected for comparison.
Scientists measured more than 6,000 proteins in the blood samples to investigate whether biological differences could reveal a higher likelihood of developing the disease.
Participants were followed for approximately 16 years, allowing researchers to compare blood proteins recorded years earlier with diagnoses made later.
The team identified 12 proteins associated with prostate cancer diagnosed more than 15 years after the samples were taken.
Seven other proteins were associated with aggressive forms of the disease.
These findings suggest that some biological processes linked to prostate cancer risk can be detected long before a clinical diagnosis.
However, the presence of these proteins does not necessarily mean that cancer was already developing when the samples were collected.
What the blood proteins revealed
One protein identified in the research was GZMK, which is produced by immune cells involved in recognising abnormal cells.
Its association with future prostate cancer risk suggests that the immune system could have an important role in determining how the disease develops.
Another protein, ANKRD1, was linked to several serious forms of prostate cancer, including cancers that had spread beyond the prostate or eventually proved fatal.
Researchers also found associations involving proteins produced by genes known to play roles in cancer development, including ERBB3, KRAS and NRAS.
These findings could help scientists investigate why certain prostate cancers remain slow-growing while others become aggressive.
Dr Zhe Huang, the study’s first author and a postdoctoral epidemiologist at Oxford Population Health, explained that prostate cancer varies considerably between patients.
Some tumours develop slowly and may never threaten a patient’s life, while others progress rapidly and require urgent treatment.
The researchers hope that studying these biological differences will eventually improve risk assessment and inform cancer prevention strategies.
Can the new test detect prostate cancer 15 years early?
The study offers an important scientific finding, but it does not establish that doctors can currently diagnose prostate cancer 15 years before symptoms appear.
Researchers identified protein patterns associated with men who were later diagnosed with the disease.
This is different from proving that a blood test can reliably determine whether an individual already has cancer or will definitely develop it.
The researchers also acknowledged that most associations were relatively modest and that some findings were not confirmed in additional analyses.
Further research must establish whether these proteins can reliably distinguish men at high risk of aggressive disease from those unlikely to develop harmful cancer.
Scientists will also need to assess whether using the markers in screening would reduce deaths without causing unnecessary investigations and treatment.
The discovery therefore represents progress towards earlier risk prediction, rather than a replacement for existing prostate cancer diagnostic procedures.
Why the discovery matters for men in the UK
Prostate cancer is the most commonly diagnosed cancer among men in the UK, excluding non-melanoma skin cancer.
More than 64,000 men are diagnosed annually, while approximately 12,000 die from the disease, according to figures discussed in recent medical research.
The difficulty is that some prostate cancers grow slowly and may never cause serious harm, while others spread and become life-threatening.
Existing prostate-specific antigen (PSA) blood tests can help identify possible prostate problems, but elevated PSA levels do not always indicate cancer.
An abnormal result may lead to further investigations, including magnetic resonance imaging (MRI) and, where necessary, a biopsy.
This creates a challenge for health services: detecting aggressive cancers early while avoiding unnecessary treatment for men whose cancers might never cause symptoms.
Oxford’s findings could eventually contribute to more personalised screening, allowing clinicians to assess cancer risk using biological information collected long before diagnosis.
New Daily Prime previously reported on an NHS initiative to identify people at increased genetic risk of cancer, including prostate cancer.
The new research investigates a different approach by examining proteins in the blood rather than relying only on inherited genetic risk.
What does the research mean for Black men?
The findings are particularly relevant to discussions about prostate cancer among Black men, who face a higher incidence of the disease than White men in the UK.
The House of Commons Library’s research briefing published on 20 October 2026 identifies Black ethnicity, increasing age and family history among important prostate cancer risk factors.
However, the Oxford findings do not yet establish whether the identified protein markers perform equally well across different ethnic populations.
This is an important question for future research, particularly if blood-protein testing is eventually considered for wider screening.
A test intended to identify people at risk must be evaluated across diverse populations to establish its accuracy, clinical usefulness and potential limitations.
New Daily Prime has previously examined the UK’s prostate cancer burden in its report, Prostate cancer overtakes breast cancer as UK’s most diagnosed, which highlighted concerns about access to early detection.
Will the NHS introduce the new test?
There is currently no indication that the blood-protein findings have been adopted as an NHS screening test.
The researchers say further validation is required before the markers can be used in routine clinical practice.
The development also comes as the UK prepares to introduce targeted prostate cancer screening for men aged 45 to 61 who have a pathogenic BRCA2 gene variant.
According to the House of Commons Library, the government accepted the UK National Screening Committee’s recommendations in June 2026, with rollout expected to begin in 2027.
The government also announced up to £18 million in additional funding to expand the TRANSFORM research study, including invitations for eligible Black men to participate. However, the UK has not introduced a universal prostate cancer screening programme for all men.
New Daily Prime previously reported that Health Secretary Wes Streeting supported further examination of prostate cancer screening, amid concerns about diagnosis and treatment delays.
What should men do now?
Men should not assume that the new discovery means a routine blood test can already predict whether they will develop prostate cancer in 15 years.
Those concerned about their risk should speak with their GP, particularly if they have a family history of the disease or belong to a higher-risk group.
Possible prostate cancer symptoms include difficulties passing urine, a weak urine stream, blood in the urine or semen, and unexplained persistent pain. These symptoms can also have causes other than cancer.
Prostate cancer may cause no noticeable symptoms in its early stages, so the absence of symptoms does not necessarily rule it out.
The NHS prostate cancer guidance provides information about symptoms, testing and treatment.
Men should also be aware that PSA testing has limitations and that decisions about further investigations should take individual circumstances into account.
What happens next?
Scientists involved in the Oxford study plan further research through the Prostate Cancer Aetiology and Prevention programme.
Their aim is to understand the biological mechanisms associated with aggressive prostate cancer and determine whether the newly identified proteins can contribute to prevention or more effective screening.
If subsequent studies demonstrate sufficient accuracy and clinical benefit, the findings could eventually influence how doctors assess prostate cancer risk.
For now, the main advance is scientific: researchers have identified measurable biological differences in blood collected many years before some men received a prostate cancer diagnosis.
The next challenge is turning those discoveries into reliable tests that can help identify dangerous cancers without exposing other men to unnecessary investigations and treatment.
Related news from New Daily Prime
